A Trump-signed bill set a deadline of Dec. 19 for the Epstein files' release. The Department of Justice said in a new court filing Monday night that there are more than 2 million documents ...

Alphabet is an artificial intelligence leader with multiple growth opportunities. Amazon is the market share leader in both e-commerce and cloud computing. Alphabet and Amazon are two smart growth ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Boston biotech is coming off ...

The Department of Justice (DOJ) on Saturday released more files, documents and photos connected to convicted sex offender Jeffrey Epstein, a day after the deadline for releasing all of the files. The ...

As AI spending continues to rise, these two Big Tech names will be best-positioned to deliver a return on investment, according to JPMorgan Shares of Alphabet have gained 65% this year thanks to ...

COLUMBIA, Mo.--(BUSINESS WIRE)--EquipmentShare.com Inc, a leader in connected jobsite technology and one of the largest equipment rental providers in the United States, today announced that it has ...

'All here for the same cause': MLK's impact echoes in Cincinnati decades after his death Activists and religious leaders walked a mile from the Freedom Center to Washington Park. Historic Cincinnati ...

At M.I.T., a new program called “artificial intelligence and decision-making” is now the second-most-popular undergraduate major. By Natasha Singer Natasha Singer covers computer science and A.I.

Welcome to a special edition of FOIA Files. This morning, the Federal Bureau of Investigation turned over dozens of emails to me that reveal some details about how FBI agents and personnel from the ...

Alphabet Inc. (NASDAQ: GOOGL) just pulled off one of the most dramatic power moves in Big Tech this year: it overtook Microsoft Corp. (NASDAQ: MSFT) to become the world's third most valuable company.

The following content is brought to you by Mashable partners. If you buy a product featured here, we may earn an affiliate commission or other compensation. Credit: Pexels Deal pricing and ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to the characterization of recombinant adeno-associated virus ...